Cancer cells frequently express genes normally active in male germ cells. ATAD2 is one of them encoding a conserved factor harbouring an AAA type ATPase domain and a bromodomain. We show here that ATAD2 is highly expressed in testis as well as in many cancers of different origins and that its high expression is a strong predictor of rapid mortality in lung and breast cancers. These observations suggest that ATAD2 acts on upstream and basic cellular processes to enhance oncogenesis in a variety of unrelated cell types. Accordingly, our functional studies show that ATAD2 controls chromatin dynamics, genome transcriptional activities and apoptotic cell response. We could also highlight some of the important intrinsic properties of its two regulatory domains, including a functional cross-talk between the AAA ATPase domain and the bromodomain. Altogether, these data indicate that ATAD2 overexpression in somatic cells, by acting on basic properties of chromatin, may contribute to malignant transformation.
Introduction
A systematic databank search for testis expressed proteins potentially capable of acting on hyperacetylated chromatin, described in (Pivot-Pajot et al., 2003) and (Boussouar et al., 2008) , attracted our attention on a putative gene of unknown function at the time of identification, now named Atad2. The analysis of the encoded protein revealed the presence of a bromodomain and an ATPase domain of the AAA family ('ATPases associated with diverse cellular activities') suggesting functions related to genome regulation. Accordingly, work on its yeast ortholog showed its role in the maintenance of boundaries, critical for the functional organization of the genome in Saccaromyces cerevisiae (Jambunathan et al., 2005; Tackett et al., 2005; Fillingham et al., 2009) , as well as in the transcriptional regulation of histone genes (Gradolatto et al., 2008) . In addition, a genetic screen in Caenorabditis elegans suggests its involvement in the silencing of repeated transgenes (Tseng et al., 2007) . Interestingly, recently several laboratories have reported the overexpression of human ATAD2 in different cancer types, and have attempted to understand its potential contribution to oncogenesis (Zou et al., 2007 (Zou et al., , 2009 Ciro et al., 2009) . One of these studies shows that human ATAD2 is a target of estrogen in human breast cancer cells, and controls the estrogen-dependent expression of several ER-a target genes (Zou et al., 2007) . Another study reveals its action as an androgen-receptor coactivator, overexpressed in hormone-independent prostate cancer cell lines as well as in a subset of prostate cancers (Zou et al., 2009) . All these investigations also highlighted the activity of ATAD2 as a transcriptional regulator, which, in addition to the estrogen and androgen receptors pathways, functions as a MYC cofactor (Ciro et al., 2009) . Although the aberrant expression of male germ cell genes in cancer cells has already been demonstrated, their contribution to cell transformation remains poorly understood. Recently we have hypothesized that the off context activity of male 'epigenetic factors' in cancer cells may induce dramatic alterations of the cell epigenome, which could in turn participate to further the epigenetic abnormalities during malignant progression (Rousseaux and Khochbin, 2009 ). Accordingly, the knowledge of the functional properties of these male germ cell 'epigenetic factors' should provide a basis for understanding the impact of their aberrant overexpression in cancer cells. This approach is exemplified here with ATAD2.
In this study, we not only show the overexpression of ATAD2 in a wide variety of solid tumours, but we also observe a strong correlation between its high expression and a short-term fatal outcome in lung and breast cancer patients. These data suggested that, when overexpressed in somatic cells, ATAD2 could be acting on basic cellular processes common to most cells, leading to cell transformation in a variety of unrelated tissues. This hypothesis is supported by our functional studies of this factor. Furthermore, our biochemical characterization of the intrinsic properties of its two domains, AAAATPase and bromodomain, could provide a basis for the development of therapeutic strategies specifically targeting ATAD2 in cancer.
Results
Atad2/ATAD2 is highly expressed in male germ cells and in somatic cancer cell lines Looking for testis-expressed factors capable of acting on hyperacetylated chromatin led us to the identification of a conserved factor of 1040 amino acids, named Atad2, whose corresponding ESTs are essentially found in testis. Further searches in databases revealed that a longer Atad2 transcript also exists in mice, encoding a protein with an additional 324 amino acids portion in its N-terminal region (Atad2-L, Supplementary Figure 1 ). This factor attracted our attention because, in addition to a bromodomain, the protein harbours a region strongly homologous to the ATPases of the AAA family. The expression profile of Atad2 in mouse tissues was investigated using primers allowing the distinction between the short and long transcripts (mAtad2-S and mAtad2-L, respectively). The longer form was detected in several tissues, as well as in early embryos ( Figure 1a ). In contrast, the shorter form was exclusively expressed in the testis. Remarkably, Atad2-L was essentially detected in testis along with the testis-specific Atad2-S (Figure 1b) . Both forms were detected in meiotic as well as in postmeiotic cells (round, elongating and condensing spermatids), in which histones are hyperacetylated and replaced ( Figure 1c ). The expression profile of human ATAD2 was also assessed and presented a strong expression in the testis (Figure 1d ). Interestingly, ATAD2 was found to be highly expressed in various human tumoral cell lines, derived from leukemia (HL60, Molt4, Jurkat), lymphoma (Daudi), lung adenocarcinoma, (A549, H1299), cervical cancer (HeLa), osteosarcoma (SAOS-2), breast tumours (MCF-7), as well as in a primate kidney-derived cell line (Cos-7) (Figures 1e and f) . As a control, the knock-down of ATAD2 by a siRNA treatment of several cell lines confirmed that the band detected by the antibody indeed corresponds to ATAD2 (Figure 1f , ' þ siRNA' lanes). No shorter form of ATAD2, similar to that detected in mice testis, was detected in these cells.
ATAD2 is overexpressed in a wide range of human cancer types and is associated with poor prognosis in lung and in breast cancer To monitor ATAD2 expression in somatic cancers, its expression levels in a series of transcriptomic data from 760 cancer samples of 14 different origins were compared to those obtained in 112 control tissue samples, taken from available data. Strikingly, nearly all the cancers considered showed a significant overexpression of ATAD2 compared to normal somatic tissues (Figure 2a ). The same analysis was performed considering the ATAD2-related gene, ATAD2B (Supplementary Figure 1) , showing no correlation between the expression of this gene and cancer (Supplementary Figure 2a) . Taking into account this extraordinary widespread and specific overexpression of ATAD2 in independent cancers, we concluded that it might constitute a very important event in malignant cell transformation and tumour progression. We therefore wanted to test the possibility that ATAD2's level of expression in the tumour could affect the patients survival probability. ATAD2 expression was analysed in a series of 271 lung cancer patients (Elisabeth and Christian Brambilla, unpublished transcriptomic data) and correlated with patients' survival. Based on their relative ATAD2 expression percentile, the patients were divided into two groups of respectively low (below 30 percentile, n ¼ 85) and high expression level (above 30 percentile, n ¼ 186). Figure 2b shows that patients expressing ATAD2 at a high level have a significantly lower chance of survival than patients expressing it at a lower level. Interestingly, the analysis of the expression of MK167, encoding the so-called Ki67 (frequently used as a proliferation marker overexpressed in aggressive tumour cells) in our series of lung cancer patients, showed that patients expressing high levels of ATAD2, also express significantly higher levels of MKI67 than patients expressing low levels of ATAD2 (Supplementary Figure 2b ). This analysis strongly supports the idea that high ATAD2 expression is associated with aggressive and highly proliferative tumour cells. A more detailed consideration of the different histopathological types of lung tumours of our series showed that all express higher levels of ATAD2 compared to our normal tissue controls (Supplementary Figure 2c) , and that the correlation between ATAD2 high expression and poor prognosis was significant essentially in the subgroup of adenocarcinoma patients (ADK, P ¼ 0.016) and near significance in large cell neuroendocrine tumours (LCNE, P ¼ 0.065) (Supplementary Figure 2d) . However, high ATAD2 expression did not affect the prognosis of the subgroups of squamous cell carcinoma patients or basaloid tumour patients (not shown).
These data suggest that the association of ATAD2 with cancer aggressivity and poor prognosis depends on additional cell type-specific factors. To extend this analysis, we used other available transcriptomic studies with survival data and tested the correlation between ATAD2 expression and survival in two other cancer types. In lymphoma ( (Lenz et al., 2008) ; GSE10846), we could not find any correlation between ATAD2 expression and survival (not shown). However, in two different studies of breast cancer patients we found that a high expression of ATAD2 was significantly correlated with poor prognosis (Supplementary Figure 2e) .
These data, although showing that ATAD2 activation occurs in most cancers, suggested that its involvement in an aggressive behavior of the cells very probably depends on the cellular context and prompted us to investigate its possible functions.
Specific interaction of the Atad2 bromodomain with acetylated K5 of H4 Nuclear soluble and non-soluble extracts were prepared from H1299 somatic cells or from mouse testes, and analysed by western blot for the presence of Atad2. Interestingly, Atad2-L was strictly associated with the nuclear non-soluble fraction, suggesting its tight association with chromatin and/or nuclear matrix ( Figure 3a , lanes 2 and 4). This is in agreement with the data of (Ciro et al., 2009) , who observed the association of human ATAD2, which corresponds to Adat2-L, with the nuclear matrix. In contrast, the short form was essentially present in the soluble fraction ( Figure 3a, lane 3) . A series of experiments was then undertaken to test the functionality of Atad2 bromodomain. These experiments were performed on the short form, because the long one could not be extracted from the chromatin fibers, except in very stringent conditions susceptible in altering the protein. A testis soluble nuclear extract containing Atad2-S was incubated with immobilized peptides corresponding to the N-terminal part of each of the four core histones, either unmodified or acetylated on all their acetyl-acceptor lysine residues. Atad2-S is specifically pulled-down with acetylated H4 (AcH4), and not with any of the other histone tails, acetylated or not (Figure 3b ). Furthermore, a similar experiment using four N-ter H4 peptides, each modified on one of the four acetyl-acceptor lysines showed that Atad2-AcH4 interaction is specifically mediated by acetylated K5 (Figure 3c ). Expression vectors for Atad2-S, either wild-type or mutated in a conserved tyrosine (Y670F, BdM mutant), corresponding to a Figure 1 Atad2/ATAD2 is highly expressed in testis and tumour cell lines. (a) Total RNA from diverse mouse tissues were reversetranscribed using random hexamer primers, and Atad2 mRNA were amplified by a 30 cycles-PCR using a forward primer specific either for the long Atad2 form (Atad2-L, upper panel) or the short one (Atad2-S, middle panel), and a common reverse primer. The quality and relative quantity of the reverse transcription products was controlled by Gapdh PCR amplifications (lower panel). (b-c) Atad2 protein was detected by western blot on 7.5% SDS-PAGE, on whole extracts of: (b) different mouse tissues; (c) whole testis and male germ cells at different stages of maturation (r ¼ round, re ¼ round and elongating, e ¼ elongating, c ¼ condensing spermatids). 20 mg of total proteins of each extract were loaded. The lower panel (Coomassie staining) shows that equivalent amounts of germ cell protein extracts were indeed loaded on the gel. (d) Total RNA from diverse human tissues was reverse-transcribed using random hexamer primers, and ATAD2 mRNA was analysed by Real Time-quantitative PCR (qPCR). The diagram represents the mean value of four experiments, two of which were normalized in using U6 RT-qPCR and the other two using GAPDH RT-qPCR, and expressed as a fold variation in each tissue compared to testis. (e) Reverse transcription and PCR, using PCR primers specific of ATAD2, were performed as in (a) on total RNA extracted from the indicated cell lines (lanes 1-10), or human testis RNA as a positive control (lane 11). (f) Anti-ATAD2 western blots were performed on 10 mg of whole cell extracts of the indicated cell lines, or of mouse testis (lane 1) as a control. For lanes 7-18: cells were treated before their collection by siRNA either scrambled (À) or targeting ATAD2 mRNA ( þ ). The quality and quantity of the samples were controlled by anti-tubulin western-blots (lower panels).
ATAD2: a new epigenome regulator C Caron et al residue known to be required for the interaction with the acetyl group within the well characterized bromodomains of yeast Bdf1 (Ladurner et al., 2003) (Figure 3d ), were prepared. As expected, Atad2-BdM was not retained on AcH4, in contrast to the wild-type protein, indicating that the bromodomain of Atad2 is functional and responsible for its specific interaction with AcH4 ( Figure 3e ). Finally, an immunoprecipitation on chromatin fibers of cells expressing Atad2-S Wt or BdM confirmed that Atad2 is indeed bound, via its bromodomain, on acetylated chromatin in cells (Figure 3f ). In this experiment, nucleosomes co-immunoprecipitated . The patients were stratified according to ATAD2 relative expression percentile ( ¼ patient's gene expression compared to the whole population of 271 lung cancer cases) into two groups: those below 30th percentile (grey dots, n ¼ 85) and those above 30th percentile (black dots, n ¼ 186). Log-rank P-value o0.0001 (Mantel-Cox).
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C Caron et al with Atad2 Wt only if the acetylation of histones was maintained by the addition of TSA in the extract (compare lanes 3 and 2), and, in contrast, no nucleosomes co-precipitated with BdM (compare lanes 5 and 6).
Targeting of AcH4 by the multimeric form of Atad2
The ability of Atad2 to oligomerize, a property shared by most AAA ATPases, was tested by co-IP assays. Hatagged Atad2-S was co-expressed in Cos7 cells either with a flag-tagged Atad2-S, or with the proteasomal AAA ATPase Rpt1 as control, and an anti-Ha immunoprecipitation was performed on cell extracts. An anti-flag western blot showed that Atad2-S strongly interacts with itself, and not with Rpt1 ( Figure 4b , compare lanes 2 and 4, middle panel). Flag-Atad2-S was then co-expressed with deleted or mutated forms of Hatagged Atad2-S, and immunoprecipitated from cell extracts with an anti-flag antibody. This experiment showed that the integrity of the AAA domain is indispensable for Atad2-S oligomerization. Indeed, no interaction could be observed when the AAA domain was deleted (DN-Atad2, Figure 4c , compare lanes 4-2 and 8-6). Moreover, a single amino acid change in the Walker A motif of the AAA domain (MtA-Atad2), known to disrupt the binding of ATP in other AAA ATPases (Sung et al., 1988; Rubin et al., 1998) , also alleviates its interaction with Flag-Atad2 Wt (Figure 4c , lane 10). Interestingly, the deletion of amino acids 823-1040 of Atad2-S diminishes the interaction of Atad2-S with itself, suggesting that its C-terminal part could be required for the stabilization of Atad2-S multimers ( Figure 4c , compare lanes 6 and 2). To analyse the influence of the AAA domain on histone binding, AcH4 pull-down experiments were then performed on different Atad2-S constructs (all harbouring the bromodomain).
Neither DN-nor MtA-Atad2-S, were retained on AcH4 (Figure 4d , lane 6 and Figure 4e , lanes 3 and 5), showing that the integrity of the AAA domain is not only required for Atad2-S oligomerization but also for its binding with AcH4. Altogether, these results, summarized in Figure 4a , show a perfect correlation between Figure 3 Atad2 bromodomain specifically interacts with H4 K5ac. (a) Differential solubility of Atad2-S and Atad2-L in nuclear extracts. Soluble extracts (S) and chromatin-associated protein extracts (C) were prepared from nuclei of human H1299 cells (left) and mice testis cells (right), and submitted to an anti-Atad2 western blot (upper panels). The short and long forms of Atad2 are indicated (Atad2-S and Atad2-L). The lower panels correspond to a Coomassie staining of the same extracts, showing histones as a control of the correct fractionation of the extracts; (b) Soluble nuclear (containing Atad2-S) extracts of mice testes cells were incubated with immobilized N-terminal tails of each core histone, either acetylated on all acetyl-acceptor lysines (Ac) or not (À). After washes, the bound proteins were eluted with the loading buffer and loaded onto an 8% SDS-PAGE. The presence of Atad2 was analysed by western blot and compared to 20% of the input; (c) Soluble nuclear extracts of mice testes were incubated with immobilized peptides corresponding to the N-ter tail of H4 tetra-acetylated (4K), not acetylated (À), or mono-acetylated on one of each acetyl-acceptor lysine (respectively K5, K8, K12 or K16); (d) Alignment of a part of the Atad2 bromodomain with the well characterized Bdf1 bromodomains. * indicates the highly conserved tyrosine, required for the binding of the acetyl group by the Bdf1 bromodomains (Ladurner et al., 2003) and changed into a phenylalanine in the Atad2 mutant (Y670F, BdM mutant); (e) A peptide pull down was performed as in (b), with peptides corresponding to non-acetylated (À) or tetra-acetylated (Ac) N-ter tail of H4, incubated with whole extracts of Cos7 cells ectopically expressing Ha-tagged mAtad2-S wild type (Wt) or mutated on its bromodomain (BdM). Atad2-S was detected by an anti-Ha western blot; (f) Chromatin was prepared from Cos7 cells ectopically expressing Wt (lanes 2, 3 and 5) or BdM (lane 6) Ha-tagged Atad2-S. Atad2 was immunoprecipitated with an anti-Ha antibody in the absence (lanes 1, 2) or presence (lanes 3-6) of Trichostatin A (TSA), which prevented chromatin deacetylation during the IP assay. Immunoprecipitated Atad2 and associated nucleosomes were recovered in loading buffer, and detected by an anti-Ha western blot (lower panels) and Coomassiestained 14% SDS-PAGE (upper panels), respectively. ATAD2: a new epigenome regulator C Caron et al the abilities of Atad2-S to form oligomers, and to bind acetylated H4 peptide. This observation indicates the Atad2-S oligomers very likely have a stronger affinity for the AcH4 peptides than the monomeric forms. We then wanted to confirm these observations by testing the ability of the endogenous protein present in testis extracts to form oligomers and to bind acetylated histone H4. Testis cytosolic and soluble nuclear Atad2-S were separated by ultracentrifugation on a glycerol gradient to isolate the monomeric form of the protein from the high molecular weight complexes. The cytoplasmic fractions mainly contained the low molecular weight forms, whereas the nuclear soluble extract contained both low and high molecular weight (higher than 660 kDa) forms of Atad2-S (Figure 5b , 'Nuc Sol' panel). A peptide pull-down performed on each fraction of this gradient shows a far better interaction of the high molecular weight forms of Atad2-S with AcH4 than of the ones with low molecular weight, confirming that the multimerization and/or complex formation of Atad2-S strongly enhances its affinity for acetylated H4 (Figure 5b , lower panel).
ATAD2 functions as a global regulator of chromatin structure and function
Three independent human cancer cell lines expressing significant amounts of ATAD2 (H1299, A549 and SAOS-2 cells; see Figure 1f ) were used to knock-down ATAD2. The purpose of this experiment was first to evaluate the role of ATAD2 as a transcriptional regulator and then to see whether ATAD2 activity could depend on the type of cells analysed. The efficiency of the siRNA treatment was checked by western blots with an anti ATAD2 antibody (Figure 6a ). The transcriptome of ATAD2 siRNA-treated cell lines was compared, by hybridization of total RNA on a 25 000 genes microarray, to that of the same cells treated with scrambled siRNA. Each hybridization was performed twice, in 'dye swap' experiments (see Supplementary Materials and methods). We considered only genes showing a deregulation with a threshold of 2-fold variation compared to cells treated with scrambled siRNA.
This analysis, interestingly, shows that ATAD2's impact on the transcriptome depends on cell types. Indeed, different numbers of genes showed an altered activity in each cell line (Supplementary Table 1 ). However, a global analysis of the genes whose expression is affected by a siATAD2 by the 'Ingenuity Pathway Analysis' software revealed that, although the genes showing altered expression after ATAD2 knockdown belong to various locations and functional categories, 'cell death' is the most enriched function in all three cell lines (Figure 6b and Supplementary  Table 2 ). Finally, to control the quality of our transcriptomic analysis we included, in addition to the first anti-ATAD2 siRNA, two new anti-ATAD2 siRNAs, and the expression of 10 of the upregulated genes was checked by RT-qPCR on mRNA of H1299. Supplementary  Figure 3 shows that 8 out of the 10 genes checked were also activated after ATAD2 knock-down by the two additional and unrelated anti-ATAD2 siRNAs. These data therefore point to ATAD2 as a regulatory factor acting on basic processes, which impact transcription, hence suggesting that the protein could be an effector of chromatin structure and function. More specifically we hypothesized that the general effect of ATAD2 on transcription could be due to its direct or indirect role on chromatin dynamics. To test this hypothesis, we generated a H1299 cell line (one of the lines used for our transcriptomic studies) stably expressing a histone H2A fused to Gfp (Gfp-H2A), and the nucleosomal Gfp-H2A turnover was monitored by a Fluorescence recovery after photobleaching (FRAP) approach. A confocal analysis of the endogenous ATAD2 distribution showed the presence of the protein in numerous nuclear dots and a siRNA treatment led to a marked decrease of the protein in these structures (Figure 6c) . FRAP experiments showed that ATAD2 downregulation, by two independent siRNAs, was associated with a significant increase in H2A turnover compared with that of cells treated with scrambled siRNA (Figure 6d) .
Finally, the presence of a bromodomain in ATAD2 suggested that it may somehow regulate histone H4 acetylation and hence affect chromatin dynamics and transcription. To test this hypothesis, ATAD2 was knocked-down in H1299 cell line using the two independent siRNAs and the level of histone H4 acetylation at its four acetyl-acceptor sites, K5, K8, K12 and K16, monitored. Supplementary Figure 4 shows that the downregulation of ATAD2 has no effect on general histone H4 acetylation in these cells. These data suggest that ATAD2 action on chromatin and transcription is not merely due to a global modulation of chromatin acetylation.
ATAD2 downregulation in cancer cells is associated with an enhanced apoptotic cell response
In the course of previous experiments we had noticed that the treatment of cells with several inducers of apoptosis systematically led to a rapid downregulation of ATAD2, which occurred even earlier than PARP The testis extracts shown in a were fractionated by ultracentrifugation on a 20-40% glycerol gradient, and the presence of Atad2 detected by western blot. All the indicated fractions from the nucleosolic extracts (Nuc Sol), were then used for AcH4 pull-down, and analysed for Atad2-S capture by anti-Atad2 western-blot (lower panel).
ATAD2: a new epigenome regulator C Caron et al cleavage (Figure 7a ). Based on this observation, we reasoned that ATAD2 downregulation, by increasing chromatin dynamics, could facilitate apoptotic chromatin alterations and therefore apoptosis itself. In addition, apoptosis-related genes constituted a significant fraction of deregulated genes after ATAD2 knock-down (Figure 6b ). All these observations prompted us to evaluate the role of ATAD2 in apoptotic cell response.
Control or anti-ATAD2 siRNA-treated H1299 cells were treated with Actinomycin D and the proportion of apoptotic cells was monitored. Figure 7b shows that, as expected, the downregulation of ATAD2 by two independent siRNAs, strongly enhances cell apoptosis. Comparable results were obtained with another genotoxic treatment, etoposide (not shown). Si-RNAmediated downregulation of ATAD2 also increased the proportion of apoptotic cells in several other tested cell lines (not shown), including SAOS, shown in Figure 7c . In the latter case, ATAD2 downregulation triggered spontaneous apoptosis without any treatment.
Discussion
Cancer cells frequently express genes, which under normal conditions are specifically or preferentially expressed in male germ cells, and whose impact in malignant cell transformation is poorly understood (Rousseaux and Khochbin, 2009 ). Here, we identified ATAD2 as one of these genes and showed its overexpression, compared with normal somatic tissues, in a strikingly large number of unrelated somatic cancers. These data confirm and extend the observation of Ciro et al. (2009) , who had detected a frequent overexpression of ATAD2 in seven different cancer types. In addition, detailed clinical information on a cohort of lung and breast cancer patients allowed us to evidence Figure 6 The ATAD2 knock-down induces global transcription changes associated with increased histone dynamics. (a) Saos, A549 and H1299 cell lines were treated with an ATAD2-targetting siRNA ( þ ) or a siRNA scrambled as control (À). The efficiency of the knock-down was monitored by an anti-ATAD2 western-blot on whole extracts prepared from one half of the cells and the loading controlled by the anti-tubulin western blot. The second half of the cells was used to analyse global gene expression on a wholegenome microarray as described in Supplementary Materials and methods. All transcriptomic data were published in GEO (http:// www.ncbi.nlm.nih.gov/geo/) under the accession number GSE12279. Detailed results of the transcriptomic analysis are presented in Supplementary Table 1. (b) Eight top 'molecular and cellular functions' and 'diseases and disorders' enriched in the lists of genes whose expression is modified by ATAD2-targetting siRNA in the respective cell lines A549, H1299 and SAOS, as well as in all three cell lines, as determined by Ingenuity Pathway Analysis (2000-2010 Ingenuity Systems). The horizontal bars represent the Àlog(P-value) of the Fisher's exact test, and the vertical line corresponds to a P-value threshold of 0.01. The P-values and the genes corresponding to each of these functions/diseases are listed in Supplementary Table 2. (c) ATAD2 downregulation after anti-ATAD2 siRNA treatment. H1299 cells were treated with an anti-ATAD2 siRNA (lower panels) or a scrambled siRNA as control (upper panels). Cells were then fixed and endogenous ATAD2 was detected by immunofluorescence using an anti-Atad2 polyclonal rabbit antibody (left panels). DNA was stained with Hoechst (right panels); (d) Increased H2A dynamics after ATAD2 knock-down evidenced by FRAP experiments. H1299 cells stably expressing Gfp-H2A were treated with anti-ATAD2 siRNAs (siATAD2), or scrambled siRNA as a control (CTL). Fluorescence intensity was measured before photobleaching (Tbleach ¼ 150 s), and at several time-points after photobleaching (shown in seconds). The graph presents the mean of fluorescence intensity recovery of five cells, for two independent experiments (experiments 1 and 2). Note that two different siRNA targeting ATAD2 (indicated as siATAD2-1 and si2ATAD2-2) were used for experiments 1 and 2, respectively.
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C Caron et al that high expression of ATAD2 strongly correlates with rapid mortality, indicating the ability of the protein to confer a very aggressive nature to the cells. This correlation was not, however, confirmed in the case of lymphoma, suggesting that ATAD2 may cooperate with cell type-specific factors to induce an aggressive behavior of the cells, a hypothesis which is in agreement with its demonstrated involvement in the estrogen and androgen receptor pathways and its activity as an MYC co-factor (Zou et al., 2007 (Zou et al., , 2009 Ciro et al., 2009) .
All these observations strongly suggest that ATAD2 could be acting on some fundamentally important cellular processes common to a variety of cell types and tissues. Our functional analysis also strongly supported this conclusion. Accordingly, we could also show that ATAD2 is capable of restricting, at a largescale level, chromatin dynamics. This could also reflect a role for ATAD2 during DNA replication and chromatin assembly. In agreement with this possibility, Helin's group has shown that ATAD2 is upregulated before/ during S phase and is found predominantly in S phase nuclei (Ciro et al., 2009) .
In addition, we have also obtained important information of the intrinsic activity of ATAD2's two functional domains, the AAA ATPase domain and the bromodomain. Indeed, the study of the testis-specific Atad2-S isoform led to the characterization of its bromodomain as a specific domain capable of specifically recognizing histone H4 K5ac. It therefore represents a new category of bromodomains, highly selective for H4 K5ac. Further investigations showed the ability ATAD2: a new epigenome regulator C Caron et al of its AAA ATPase domain to regulate acetylated chromatin binding indicating that it could represent a good target for therapeutic inhibitors. The specificity of Atad2 for the binding of H4 K5ac could be indicative of its function. The presence of AcK5 on histone H4, associated with K12ac, has been essentially described in newly synthesized histones (Sobel et al., 1995) . It is possible that Atad2 as discussed above, possesses some type of histone chaperone activity, a hypothesis, which could fit with its role in chromatin dynamics observed here. Histone H4 K5 acetylation also has a critical role in the regulation of transcription. Indeed, histone H4 K5 deacetylation was shown to be required for the binding of SMRT transcriptional co-repressor through its second SANT domain, which specifically binds non acetylated H4 tail (Yu et al., 2003; Hartman et al., 2005) . In this context, SMRT/HDAC3 deacetylates K5 and could initiate a self propagation event (Hartman et al., 2005) . With this respect, an alternative role of Atad2-K5ac binding could be its ability to antagonize the propagation of deacetylase complexes such as SMRT/HDAC3 and act as a boundary. This is in fact a very plausible mechanism as the yeast Atad2 ortholog, Yta7, has been shown to be a crucial component of complexes, which bind discrete regions of the genome including known boundaries between silent and active chromatin (Tackett et al., 2005) .
We found however that, although harbouring the same bromodomain as Atad2-S, Atad2L/ATAD2 does not interact with AcH4 ( (Ciro et al., 2009 ) and our data not shown) strongly suggesting that the Nterminal region of ATAD2 (which is removed in Atad2-S) has a regulatory role. Indeed, through its interaction with specific partners or modifications, it may let the rest of the protein behave as Atad2-S, multimerize and bind acetylated chromatin. In the absence of such specific regulation of the N-terminal domain, Atad2-L/ATAD2 may act as a boundary as does the yeast Atad2 ortholog, Yta7, although presenting a non-functional bromodomain (Jambunathan et al., 2005; Gradolatto et al., 2008) . This activity of ATAD2 could also explain the chromatin 'freezing' property of the protein revealed here, in addition to its role as a co-activator in specific regulatory pathways recently described (Zou et al., 2007 (Zou et al., , 2009 Ciro et al., 2009) .
Based on the data presented here, we propose that the chromatin freezing due to ATAD2 overexpression is an important determinant in malignant cell transformation. This conclusion is in line with and generalizes the previous observation that the overexpression of factors restricting chromatin dynamics such as HP1-a (De Koning et al., 2009 ) could highly stimulate oncogenesis.
Materials and methods
Cloning of Atad2 cDNA, plasmid constructs and expression analyses by PCR and qPCR Murine full length Atad2-S cDNA was amplified by PCR from a Marathon-ready testis cDNA library (Clontech, St Germain en Lay, France) cloned in expression vectors as detailed in Supplementary Materials and methods. Total RNA from cell lines was extracted with Trizol reagent (Invitrogen, Cergy Pontoise, France) or purchased from BD Bioscience (Le Pont de Claix, France). Expression analyses were performed as detailed in Materials and methods.
Antibodies Anti-Atad2 antibody was generated by three injections in rabbit of 300 mg of a purified recombinant protein corresponding to amino acids 1-112 of mAtad2-S fused to 6XHis tag. The rabbit's serum was purified on an affinity column obtained by coupling the Atad2 recombinant protein on a CnBr-activated resin. Other antibodies were purchased from Pharmingen (Le Pont de Claix, France) (anti-Parp), Covance (Paris, France) (rabbit anti-Ha used in western-blots), Roche (Meylan, France) (rat high affinity anti-Ha used in immunoprecipitation) and Sigma (St Quentin, France) (anti-flag M2, antiTubulin).
Co-immunoprecipitation (IP), chromatin IP and peptide pull-down Immunoprecipitation assays were performed as described in (Col et al., 2005) and the pull-down conditions are described in the Supplementary Materials and methods.
Testis cell extracts and glycerol gradients Testis cytoplasm/nucleus fractionation was performed by dissociation of two testes in a potter with 2 ml of lysis buffer (0.34 M saccharose, 60 mM KCl, 15 mM NaCl, 15 mM Tris-HCl pH 7.4, 0.65 mM spermidine, 2 mM EDTA, 0.5 mM EGTA, 0.03% Triton X-100, 0.1 mM DTT, 0.5 mM PMSF), filtration on 100 mm filters, and centrifugation (10 0 , 1500 r.p.m.). The supernatant, corresponding to the cytoplasmic extract, was kept. The pellet, containing the nuclei of testis cells, was resuspended in 1 ml of LSDB500 buffer. After 15 min incubation on ice, a nuclear soluble extract was separated from insoluble chromatin fibres by centrifugation (10 min, 12 000 r.p.m.). 200 ml of testis extracts were deposited on 2 ml of a 20-40% glycerol gradient (in Tris 50 mM, MgCl2 2.5 mM, DTT 1 mM, anti-protease cocktail: complete mini EDTA-free, Roche), and separated by ultracentrifugation (Sorvall RP55S rotor, 50 000 r.p.m., 3 h, 4 1C). 120 ml fractions were collected and analysed by western blots for the presence of Atad2.
Cell culture, transfection, treatments and immunoflurescence Cell culture, transfection conditions, siRNAs and immunofluorescence techniques are described in the Supplementary Materials and methods. FRAP was preformed as follows. H1299 cells stably expressing Gfp-H2A were established after transfection with 10 mg of pEGFP-H2A and 1 mg of a G418 resistance-containing vector, and selection of cells in a G418-containing medium. The pool of G418-resistant cells was then used to isolate individual Gfp-H2A expressing clones. Cells were grown on Lab-Tek-chambered coverglasses (Nalgen Nunc International, Roskilde, Denmark) and maintained under standard culture conditions. siRNA were transfected during 48 h. Images were acquired on a Zeiss LSM510 system using a Planapochromat Â 40 water immersion objective. GFP was excited with a 488 nm Argon 2 laser (power varying from 0.1 to 2%). FRAP was conducted as already described (Perche et al., 2000) . Briefly, an outlined region was bleached with a full power laser and recovery was monitored repetitively (each 5 min) during approximately 1 h and 40 min.
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